NCT00378196View on ClinicalTrials.gov

Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

September 30, 2007

Study Completion Date

December 31, 2008

Conditions
Telangiectasia
Interventions
DRUG

Ranibizumab

0.3 mg/0.05 ml dose

DRUG

Ranibizumab

0.5 mg/0.05 ml dose

Trial Locations (1)

21287

The Wilmer Eye Institute at Johns Hopkins, Baltimore

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Johns Hopkins University

OTHER

NCT00378196 - Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial | Biotech Hunter | Biotech Hunter